Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Liquidia Corp (NQ: LQDA ) 10.46 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Liquidia Corp < Previous 1 2 3 Next > Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024 November 04, 2024 From Liquidia Corporation Via GlobeNewswire United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent October 07, 2024 From Liquidia Corporation Via GlobeNewswire Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606) October 02, 2024 From Liquidia Corporation Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Liquidia, Napco, and Franklin and Encourages Investors to Contact the Firm September 30, 2024 From Bragar Eagel & Squire Via GlobeNewswire Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting September 30, 2024 From Liquidia Corporation Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Paragon 28, Centuri, Liquidia, and Elastic and Encourages Investors to Contact the Firm September 16, 2024 From Bragar Eagel & Squire Via GlobeNewswire Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million September 16, 2024 From Liquidia Corporation Via GlobeNewswire Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement September 11, 2024 From Liquidia Corporation Via GlobeNewswire Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc. (LQDA) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings September 06, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc. (LQDA) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings August 29, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Liquidia to Present at Upcoming Investor Conferences August 28, 2024 From Liquidia Corporation Via GlobeNewswire LIQUIDIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm August 27, 2024 From Bragar Eagel & Squire Via GlobeNewswire Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Liquidia Corporation (LQDA) August 27, 2024 From Kirby McInerney LLP Via Business Wire Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD August 22, 2024 From Liquidia Corporation Via GlobeNewswire LQDA Investors Have Opportunity to Join Liquidia Corporation Securities Fraud Investigation with the Schall Law Firm August 19, 2024 From The Schall Law Firm Via Business Wire U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) August 19, 2024 From Liquidia Corporation Via GlobeNewswire Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions August 16, 2024 From Liquidia Corporation Via GlobeNewswire Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 07, 2024 From Liquidia Corporation Via GlobeNewswire Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024 July 31, 2024 From Liquidia Corporation Via GlobeNewswire Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH) June 18, 2024 From Liquidia Corporation Via GlobeNewswire District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch June 03, 2024 From Liquidia Corporation Via GlobeNewswire Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference May 29, 2024 From Liquidia Corporation Via GlobeNewswire Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update May 13, 2024 From Liquidia Corporation Via GlobeNewswire Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD May 10, 2024 From Liquidia Corporation Via GlobeNewswire Liquidia Corporation to Present at BofA Securities Health Care Conference 2024 May 07, 2024 From Liquidia Corporation Via GlobeNewswire Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024 May 07, 2024 From Liquidia Corporation Via GlobeNewswire Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference April 02, 2024 From Liquidia Corporation Via GlobeNewswire Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder April 01, 2024 From Liquidia Corporation Via GlobeNewswire Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update March 13, 2024 From Liquidia Corporation Via GlobeNewswire Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024 March 06, 2024 From Liquidia Corporation Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
